Abstract:Background: Numerous reports have shown that a combination of two or more drugs leads to better cancer treatment. Inhibitors of zeste homology 2 and epidermal growth factor receptor have been widely used in cancer treatments. However, the mechanisms of the combined use of these two drugs remain elusive. Methods: Sul forhodamine B assays and Alexa Fluor (R)-488 Annexin V/Dead Cell Apoptosis Kit were used to detect the cell proliferation and cell apoptosis in vitro, respectively. Western blotting analysis was used to detect the relative protein expression, and xenografted tumor was generated in nude mice to evaluate the effect in vivo. Results: Treatment with either Gefitinib ranging from 0 to 12.5 mu M or GSK126 ranging from 0 to 8.3 mu M caused adore-dependent decrease in the cell survival fraction, and the combination of Gefitinib at 12.5 mu M and GSK126 at 8.3 mu M caused further significant decrease. The combination indexes were 0.061, 0.591, 0.713, and 0.371 for MGC803, A549, PC-3, and MDB-MA-231, respectively. In MGC803 cells, the combination of GSK126 and Gefitinib synergistically induced cell apoptosis (56.2%), which was markedly higher as compared to either drug alone (7.6% and 10.6%, P<0.05). Treatment with either Gefitinib or GSK126 alone induced a significant increase in cell apoptosis in LC3-II and p-ULK, whereas the combination of the two induced a further increase. Pretreatment with an autophagy inhibitor, 3-methyladenine, prevented the apoptosis induced by the combined use of Gefitinib and GSK126. In addition, the combined use of Gefitinib and GSK126 also inhibited the activation of mammalian target of rapamycin signaling pathway. Furthermore, the combined use of GSK126 and Gefitinib synergistically inhibited xenografted tumor proliferation. Conclusion: The combined use of GSK126 and Gefitinib exerts a synergic effect on tumor growth inhibition both in vitro and in vivo through inducing autophagy and promoting apoptosis. Therefore, GSK126 and Gefitinib in combination may be considered as a potential strategy in treating solid tumor clinically.

Inhibitory Effects and Molecular Mechanisms of Pentagalloyl Glucose in Combination with 5-FU on Aggressive Phenotypes of HepG2 Cells.

Polyunsaturated Fatty Acids Augment Tumoricidal Action Of 5-Fluorouracil On Gastric Cancer Cells By Their Action On Vascular Endothelial Growth Factor, Tumor Necrosis Factor-Alpha And Lipid Metabolism Related Factors

In vitro anti-hepatocellular carcinogenesis of 1,2,3,4,6-Penta-O-galloyl-β-D-glucose

Parthenolide Augments the Anticancer Effects of 5-Fluorouracil on Cell Apoptosis and Decreased Nf-Kappa B Activity in A Gastric Cancer Cell Line

Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2‐Deoxy‐d‐glucose

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Sensitization of Gastric Cancer Cells to Alkylating Agents by Glaucocalyxin B Via Cell Cycle Arrest and Enhanced Cell Death.

Combination of the FGFR4 Inhibitor PD173074 and 5-Fluorouracil Reduces Proliferation and Promotes Apoptosis in Gastric Cancer.

Investigation of the inhibition effect of 1,2,3,4,6-pentagalloyl-β-D-glucose on gastric cancer cells based on a network pharmacology approach and experimental validation

Anti-metastatic effects of 1,2,3,4,6-Penta-O-galloyl-β-D-glucose in colorectal cancer: Regulation of cathepsin B-mediated extracellular matrix dynamics and epithelial-to-mesenchymal transition

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.

Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways

Apoptotic and DNA Damage Effect of 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose in Cisplatin-Resistant Non-Small Lung Cancer Cells via Phosphorylation of H2AX, CHK2 and p53

Pentagalloylglucose disrupts the PALB2-BRCA2 interaction and potentiates tumor sensitivity to PARP inhibitor and radiotherapy

Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice

Propyl gallate inhibits hepatocellular carcinoma cell growth through the induction of ROS and the activation of autophagy

Cistanche tubulosa Phenylethanoid Glycosides Induce Apoptosis of Hepatocellular Carcinoma Cells by Mitochondria-Dependent and MAPK Pathways and Enhance Antitumor Effect through Combination with Cisplatin